Abbott Laboratories (ABT)

42.33
0.65 1.56
NYSE : Health Care
Prev Close 41.68
Open 41.73
Day Low/High 41.56 / 42.34
52 Wk Low/High 36.00 / 46.38
Volume 5.96M
Avg Volume 9.78M
Exchange NYSE
Shares Outstanding 1.47B
Market Cap 62.02B
EPS 2.90
P/E Ratio 32.71
Div & Yield 1.04 (2.50%)

Latest News

Fueling Performance With Fat: EAS® Launches First Ketogenic Meal Replacement For Athletes

Fueling Performance With Fat: EAS® Launches First Ketogenic Meal Replacement For Athletes

MYOPLEX® KETOGENIC DELIVERS THE RIGHT AMOUNT OF NUTRIENTS NEEDED TO SUPPORT A KETOGENIC REGIMEN AND HELP ATHLETES ACHIEVE THEIR BODY AND PERFORMANCE GOALS

Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics

Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics

The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.

Closing Bell: LionsGate's 'Blair Witch' Set to Own Box Office; U.S. Stocks Fall

Closing Bell: LionsGate's 'Blair Witch' Set to Own Box Office; U.S. Stocks Fall

U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.

Abbott (ABT) Stock Higher as Johnson & Johnson to Buy Medical Optics Unit

Abbott (ABT) Stock Higher as Johnson & Johnson to Buy Medical Optics Unit

Abbott Laboratories (ABT) will sell its eye surgery unit to Johnson & Johnson (JNJ) for $4.325 billion in cash.

Abbott To Sell Abbott Medical Optics To Johnson & Johnson For $4.325 Billion

Abbott To Sell Abbott Medical Optics To Johnson & Johnson For $4.325 Billion

- Abbott continues to shape its portfolio for long-term growth

AbbVie's Battle Royale

AbbVie's Battle Royale

Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?

4 Market Segments to Avoid

4 Market Segments to Avoid

These sectors are full of high-priced, low-growth stocks.

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

Cramer is sticking with International Paper and likes Advanced Micro Devices.

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

This is not the time to sell in a panic, Cramer says.

Can Abbott Labs Find a Cure for Its Ailing Shares?

Can Abbott Labs Find a Cure for Its Ailing Shares?

Abbott Labs shares have been all over the place in the last year as the company makes deals. Investors are wondering if they should hold on.

Will Abbott Laboratories (ABT) Stock Be Helped by Mediation in Alere Merger?

Will Abbott Laboratories (ABT) Stock Be Helped by Mediation in Alere Merger?

Abbott Laboratories (ABT) and Alere (ALR) agreed today to work with a mediator to solve issues in their ongoing merger dispute.

Abbott Named Industry Leader for Responsible and Sustainable Business for Four Consecutive Years on the Dow Jones Sustainability Index (DJSI)

Abbott Named Industry Leader for Responsible and Sustainable Business for Four Consecutive Years on the Dow Jones Sustainability Index (DJSI)

- Achieves top industry scores in all three categories of economic, environmental and social performance, and more than doubles the overall average industry score

Reaction to St. Jude Cybersecurity Threat May Be Overdone

Reaction to St. Jude Cybersecurity Threat May Be Overdone

The cardiac device maker has filed a lawsuit against the Muddy Waters, claiming the short-seller intentionally disseminated false and misleading information.

Zoetis Remains Attractive Alternative Healthcare Investment

Zoetis Remains Attractive Alternative Healthcare Investment

Zoetis' valuation doesn't reflect opportunities from innovation, operational improvements, and capital allocation, according to one analyst.

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Potential targets of the medical device and diagnostics giant might request stricter parameters when structuring a deal, company followers say.

Alere Asks for September Trial in Case Against Abbott

Alere Asks for September Trial in Case Against Abbott

Alere claims that Abbott is slow-rolling the antitrust process on the companies' merger in an effort to kill the deal.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Abbott's Acquisitions in Question as Issues Arise About Alere, St. Jude

Abbott's Acquisitions in Question as Issues Arise About Alere, St. Jude

The provider of point-of-care testing has filed a suit in Delaware Chancery Court against Abbott in an effort to complete their pending deal. Meanwhile, St. Jude, gets a griping short-seller.

Abbott (ABT) Stock Lower, Alere Sues to Force $5.8 Billion Deal

Abbott (ABT) Stock Lower, Alere Sues to Force $5.8 Billion Deal

Alere (ALR) sued Abbott (ABT) on Friday saying the medical device company failed to get U.S. antitrust approval for its merger.

Why Abbott Laboratories (ABT) Stock Is Up Today

Why Abbott Laboratories (ABT) Stock Is Up Today

Abbott Laboratories (ABT) stock was increasing Thursday afternoon as Muddy Waters attempts to break up the company's proposed acquisition of St. Jude (STJ).

Analysts' Actions -- Abbott Labs, Garmin, Nordson, NetApp and More

Analysts' Actions -- Abbott Labs, Garmin, Nordson, NetApp and More

Here are Wednesday's top research calls, including upgrades for Abbott Labs and NetApp, and downgrades for Garmin and Nordsom.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABT, AXLL, BOKF, FLY, KCAP, RWC Downgrades: BBRG, CCOI, DL, EMG, FLO, HWBK, IIJI, INOD, MTH, NOA, SMCI, SNY, TGNA Initiations: BUFF, GI, NSA Read on to get TheStreet Quant Ratings' detailed report:

This High-Quality Dividend Stock Belongs in Your Portfolio Now

This High-Quality Dividend Stock Belongs in Your Portfolio Now

Abbott Laboratories (ABT) has great growth prospects and has paid increasing dividends for more than 40 years. Here's why this Dividend Aristocrat should be in your investment portfolio.

Abbott Laboratories (ABT) Stock Declines, Alere Deal Looks Uncertain

Abbott Laboratories (ABT) Stock Declines, Alere Deal Looks Uncertain

Abbott Laboratories (ABT) said Alere (ALR) hasn't disclosed key information, making the company question whether its proposed $5.8 billion deal will close.

Insiders Love These 5 Stocks Right Now

Insiders Love These 5 Stocks Right Now

Insiders at these companies have been scooping up shares of their own stock lately.